292 related articles for article (PubMed ID: 30624727)
21. APOBEC3B is preferentially expressed at the G2/M phase of cell cycle.
Hirabayashi S; Shirakawa K; Horisawa Y; Matsumoto T; Matsui H; Yamazaki H; Sarca AD; Kazuma Y; Nomura R; Konishi Y; Takeuchi S; Stanford E; Kawaji H; Murakawa Y; Takaori-Kondo A
Biochem Biophys Res Commun; 2021 Mar; 546():178-184. PubMed ID: 33592502
[TBL] [Abstract][Full Text] [Related]
22. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.
Kanu N; Cerone MA; Goh G; Zalmas LP; Bartkova J; Dietzen M; McGranahan N; Rogers R; Law EK; Gromova I; Kschischo M; Walton MI; Rossanese OW; Bartek J; Harris RS; Venkatesan S; Swanton C
Genome Biol; 2016 Sep; 17(1):185. PubMed ID: 27634334
[TBL] [Abstract][Full Text] [Related]
23. The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities.
Green AM; Weitzman MD
DNA Repair (Amst); 2019 Nov; 83():102700. PubMed ID: 31563041
[TBL] [Abstract][Full Text] [Related]
24. Elucidation of the Complicated Scenario of Primate APOBEC3 Gene Evolution.
Uriu K; Kosugi Y; Suzuki N; Ito J; Sato K
J Virol; 2021 May; 95(12):. PubMed ID: 33789992
[TBL] [Abstract][Full Text] [Related]
25. The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
Serebrenik AA; Argyris PP; Jarvis MC; Brown WL; Bazzaro M; Vogel RI; Erickson BK; Lee SH; Goergen KM; Maurer MJ; Heinzen EP; Oberg AL; Huang Y; Hou X; Weroha SJ; Kaufmann SH; Harris RS
Clin Cancer Res; 2020 Jul; 26(13):3397-3407. PubMed ID: 32060098
[TBL] [Abstract][Full Text] [Related]
26. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
Matsumoto T; Shirakawa K; Yokoyama M; Fukuda H; Sarca AD; Koyabu S; Yamazaki H; Kazuma Y; Matsui H; Maruyama W; Nagata K; Tanabe F; Kobayashi M; Shindo K; Morishita R; Sato H; Takaori-Kondo A
Sci Rep; 2019 Jun; 9(1):8307. PubMed ID: 31165764
[TBL] [Abstract][Full Text] [Related]
27. Monitoring APOBEC3A protein levels in human cancer cells.
Dananberg A; Maciejowski J
Methods Cell Biol; 2024; 182():313-327. PubMed ID: 38359985
[TBL] [Abstract][Full Text] [Related]
28. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity.
Ma W; Ho DW; Sze KM; Tsui YM; Chan LK; Lee JM; Ng IO
Mol Carcinog; 2019 May; 58(5):643-653. PubMed ID: 30575099
[TBL] [Abstract][Full Text] [Related]
29. Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases.
Mahieux R; Suspène R; Delebecque F; Henry M; Schwartz O; Wain-Hobson S; Vartanian JP
J Gen Virol; 2005 Sep; 86(Pt 9):2489-2494. PubMed ID: 16099907
[TBL] [Abstract][Full Text] [Related]
30. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
31. Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma.
Xu R; Zhang X; Zhang W; Fang Y; Zheng S; Yu XF
Hepatology; 2007 Dec; 46(6):1810-20. PubMed ID: 17847074
[TBL] [Abstract][Full Text] [Related]
32. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
[TBL] [Abstract][Full Text] [Related]
33. Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B.
Akre MK; Starrett GJ; Quist JS; Temiz NA; Carpenter MA; Tutt AN; Grigoriadis A; Harris RS
PLoS One; 2016; 11(5):e0155391. PubMed ID: 27163364
[TBL] [Abstract][Full Text] [Related]
34. Structural Characterization of a Minimal Antibody against Human APOBEC3B.
Tang H; Demir Ö; Kurniawan F; Brown WL; Shi K; Moeller NH; Carpenter MA; Belica C; Orellana K; Du G; LeBeau AM; Amaro RE; Harris RS; Aihara H
Viruses; 2021 Apr; 13(4):. PubMed ID: 33921405
[TBL] [Abstract][Full Text] [Related]
35. Host restriction of murine gammaherpesvirus 68 replication by human APOBEC3 cytidine deaminases but not murine APOBEC3.
Minkah N; Chavez K; Shah P; Maccarthy T; Chen H; Landau N; Krug LT
Virology; 2014 Apr; 454-455():215-26. PubMed ID: 24725948
[TBL] [Abstract][Full Text] [Related]
36. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons.
Jost S; Turelli P; Mangeat B; Protzer U; Trono D
J Virol; 2007 Oct; 81(19):10588-96. PubMed ID: 17652382
[TBL] [Abstract][Full Text] [Related]
37. Enzyme cycling contributes to efficient induction of genome mutagenesis by the cytidine deaminase APOBEC3B.
Adolph MB; Love RP; Feng Y; Chelico L
Nucleic Acids Res; 2017 Nov; 45(20):11925-11940. PubMed ID: 28981865
[TBL] [Abstract][Full Text] [Related]
38. APOBEC3-mediated restriction of RNA virus replication.
Milewska A; Kindler E; Vkovski P; Zeglen S; Ochman M; Thiel V; Rajfur Z; Pyrc K
Sci Rep; 2018 Apr; 8(1):5960. PubMed ID: 29654310
[TBL] [Abstract][Full Text] [Related]
39. APOBEC3B lysine residues are dispensable for DNA cytosine deamination, HIV-1 restriction, and nuclear localization.
Molan AM; Hanson HM; Chweya CM; Anderson BD; Starrett GJ; Richards CM; Harris RS
Virology; 2017 Nov; 511():74-81. PubMed ID: 28841445
[TBL] [Abstract][Full Text] [Related]
40. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.
Refsland EW; Stenglein MD; Shindo K; Albin JS; Brown WL; Harris RS
Nucleic Acids Res; 2010 Jul; 38(13):4274-84. PubMed ID: 20308164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
